{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:07:57Z","timestamp":1768702077568,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Remimazolam is a relatively new benzodiazepine with growing use in procedural sedation and general anaesthesia. Initiated by case reports, the physical incompatibility of remimazolam with ringer\u2019s acetated and ringer\u2019s lactated solution has been reported. More recently, remifentanil, fentanyl, rocuronium, vecuronium, dexmedetomidine, and midazolam, have been investigated and suggested safe for coadministration with remimazolam. Apart from case reports, incompatibility for other frequently used drugs remains unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Sixty-five drugs and intravenous fluids were tested for possible precipitation with remimazolam in a simulated y-site administration. Equal volumes of the test drug were injected into the remimazolam solution, examined and photo documented at 1, 15, 30 and 60\u00a0min after mixture. Examination was taken by two independent investigators. pH was measured before, and 60\u00a0min after mixing the drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventeen (26.15%) drugs or fluids showed precipitation, 47 (72.31%) did not show any sign of interaction. Propofol could not be assessed, because of the turbidity of the substance itself. Precipitation occurred immediately and remained stable in all timestamps. The incompatible drug-remimazolam-mixtures had a median pH of 7.15 (6.67, 8.01), the non-precipitating mixtures a median pH of 4.75 (3.8, 5.6). The pH-values of both groups were significantly different (Mann-Whitney-U-test; <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.00001). There is an increasing risk for precipitation with more basic baseline pH-levels of the tested drug. No interaction was seen in baseline pH below 5.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Remimazolam (Byfavo<jats:sup>\u00ae<\/jats:sup>) is incompatible with ampicillin\/ sulbactam, calcium gluconate, clindamycin, dexamethasone, dimenhydrinate, an 148mval\/l electrolyte - glucose 1% solution (E148G1<jats:sup>\u00ae<\/jats:sup>), furosemide, a 4% gelatine volume expander (gelafundin<jats:sup>\u00ae<\/jats:sup><jats:sup>)<\/jats:sup>, heparin sodium, insulin, meropenem, sodium bicarbonate 8.4%, prednisolone, the crystalloid infusions jonosteril<jats:sup>\u00ae<\/jats:sup> and sterofundin<jats:sup>\u00ae<\/jats:sup>, thiopental and tranexamic acid. The results strongly affirm remimazolam\u2019s safety requirements: A separate line for remimazolam and an approved compatible baseline infusion is mandatory and an alternative way to administer bolus medication is required.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12871-024-02613-7","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T08:03:33Z","timestamp":1720685013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Incompatibility of the short-acting benzodiazepine remimazolam with common perioperative medication"],"prefix":"10.1186","volume":"24","author":[{"given":"Pascal","family":"Hofmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Br\u00fcmmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berthold","family":"Drexler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"1","key":"2613_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/01.anes.0000267503.85085.c0","volume":"107","author":"GJ Kilpatrick","year":"2007","unstructured":"Kilpatrick GJ, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007;107(1):60\u20136.","journal-title":"Anesthesiology"},{"key":"2613_CR2","unstructured":"AG P. PAION web page. 2023 [cited 2023 13.04.2023]; https:\/\/www.paion.com\/de\/produkte\/remimazolam\/leitsubstanz-remimazolam."},{"key":"2613_CR3","doi-asserted-by":"publisher","first-page":"690875","DOI":"10.3389\/fphar.2021.690875","volume":"12","author":"GJ Kilpatrick","year":"2021","unstructured":"Kilpatrick GJ. Remimazolam: Non-clinical and Clinical Profile of a New Sedative\/Anesthetic Agent. Front Pharmacol. 2021;12:690875.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2613_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1213\/ANE.0b013e31823f0c28","volume":"115","author":"LJ Antonik","year":"2012","unstructured":"Antonik LJ, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012;115(2):274\u201383.","journal-title":"Anesth Analg"},{"issue":"5","key":"2613_CR5","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1213\/ANE.0b013e3182a705ae","volume":"117","author":"MT Worthington","year":"2013","unstructured":"Worthington MT, et al. A phase ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg. 2013;117(5):1093\u2013100.","journal-title":"Anesth Analg"},{"issue":"2","key":"2613_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1213\/ANE.0b013e318241f68a","volume":"115","author":"HR Wiltshire","year":"2012","unstructured":"Wiltshire HR, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012;115(2):284\u201396.","journal-title":"Anesth Analg"},{"key":"2613_CR7","unstructured":"AG P, ANNEX I SUMMARY OF PRODUCT, CHARACTERISTICS. 2021 [cited 2023 13.04.2023]; https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/byfavo-epar-product-information_en.pdf."},{"issue":"4","key":"2613_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/ACO.0000000000000877","volume":"33","author":"JR Sneyd","year":"2020","unstructured":"Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020;33(4):506\u201311.","journal-title":"Curr Opin Anaesthesiol"},{"issue":"3","key":"2613_CR9","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.bja.2020.11.021","volume":"126","author":"H Sasaki","year":"2021","unstructured":"Sasaki H, Hoshijima H, Mizuta K. Ringer\u2019s acetate solution-induced precipitation of remimazolam. Br J Anaesth. 2021;126(3):e87\u20139.","journal-title":"Br J Anaesth"},{"issue":"2","key":"2613_CR10","first-page":"234","volume":"73","author":"JM Sung","year":"2023","unstructured":"Sung JM, Kim KN, Jun YE. Precipitation of remimazolam in coadministration with plasma-lyte 148: two case reports. Braz J Anesthesiol. 2023;73(2):234\u20135.","journal-title":"Braz J Anesthesiol"},{"issue":"7","key":"2613_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1258\/shorts.2011.011031","volume":"2","author":"S Khan","year":"2011","unstructured":"Khan S, Stannard N, Greijn J. Precipitation of thiopental with muscle relaxants: a potential hazard. JRSM Short Rep. 2011;2(7):58.","journal-title":"JRSM Short Rep"},{"issue":"1","key":"2613_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/2110-5820-2-28","volume":"2","author":"A Foinard","year":"2012","unstructured":"Foinard A, et al. Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility. Ann Intensive Care. 2012;2(1):28.","journal-title":"Ann Intensive Care"},{"key":"2613_CR13","doi-asserted-by":"crossref","unstructured":"Mena M. A., Evaluation of strategies for reducing Vancomycin-Piperacillin\/Tazobactam incompatibility. Pharmaceutics, 2023. 15(8).","DOI":"10.3390\/pharmaceutics15082069"},{"issue":"7","key":"2613_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jclinane.2011.04.004","volume":"23","author":"TA Alston","year":"2011","unstructured":"Alston TA. Precipitation of sugammadex by protamine. J Clin Anesth. 2011;23(7):593.","journal-title":"J Clin Anesth"},{"key":"2613_CR15","doi-asserted-by":"crossref","unstructured":"Eckle VS, Grasshoff C. [Precipitation of piritramide and cefazolin. Study of the dependence on concentration and pH] Anaesthesist, 2013. 62(11): pp. 898\u2013901.","DOI":"10.1007\/s00101-013-2246-y"},{"key":"2613_CR16","doi-asserted-by":"crossref","unstructured":"Werzer C, Sch\u00e4fer S, Hofmann-Kiefer K. [Drug interaction between ceftriaxone and theodrenaline\/cafedrine: A case example] Anaesthesiologie, 2023. 72(2): pp. 109\u2013112.","DOI":"10.1007\/s00101-022-01217-5"},{"key":"2613_CR17","doi-asserted-by":"crossref","unstructured":"Kondo M et al. Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration. Am J Health Syst Pharm, 2022.","DOI":"10.1093\/ajhp\/zxac262"},{"issue":"2","key":"2613_CR18","doi-asserted-by":"publisher","first-page":"e20200501","DOI":"10.1590\/0034-7167-2020-0501","volume":"74","author":"JH Garcia","year":"2021","unstructured":"Garcia JH, et al. In(compatibility) of intravenous drugs in critical units: adult cohort. Rev Bras Enferm. 2021;74(2):e20200501.","journal-title":"Rev Bras Enferm"},{"issue":"6","key":"2613_CR19","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1021\/acs.molpharmaceut.2c00983","volume":"20","author":"N Nilsson","year":"2023","unstructured":"Nilsson N, et al. Co-administration of intravenous drugs: rapidly troubleshooting the solid form composition of a Precipitate in a multi-drug mixture using On-Site Raman Spectroscopy. Mol Pharm. 2023;20(6):2853\u201363.","journal-title":"Mol Pharm"},{"issue":"4","key":"2613_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2146\/ajhp080059","volume":"66","author":"DW Newton","year":"2009","unstructured":"Newton DW. Drug incompatibility chemistry. Am J Health Syst Pharm. 2009;66(4):348\u201357.","journal-title":"Am J Health Syst Pharm"},{"key":"2613_CR21","unstructured":"Stangroom J. Mann-Whitney U Test Calculator. 2023 [cited 2023 13.04.2023]; https:\/\/www.socscistatistics.com\/tests\/mannwhitney\/default.aspx."},{"issue":"4","key":"2613_CR22","first-page":"289","volume":"46","author":"SM Rao","year":"2002","unstructured":"Rao SM, Nagendranath V. ARTERIAL BLOOD GAS MONITORING. Indian J Anaesth. 2002;46(4):289\u201397.","journal-title":"Indian J Anaesth"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-024-02613-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-024-02613-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-024-02613-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T08:04:22Z","timestamp":1720685062000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-024-02613-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2613"],"URL":"https:\/\/doi.org\/10.1186\/s12871-024-02613-7","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Hofmann P, Bachmann L and Drexler B were part of T\u00fcbingen\u2019s study team for NCT03661489 (Efficacy and safety of remimazolam compared to propofol for intravenous anesthesia during elective surgery). The Department of Anaesthesiology and Intensive Care T\u00fcbingen received funding for this participation. The authors gained no personal individual benefits.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}